Table 2.
Univariate analysis for the add-on of non-steroid immunosuppressants to steroid treatment.
| Variable | P | HR | 95.0% CI for HR | |
|---|---|---|---|---|
| Lower | Upper | |||
| Sex | 0.994 | 0.998 | 0.529 | 1.881 |
| Early-onset | 0.249 | 0.599 | 0.251 | 1.430 |
| Onset age, years | 0.184 | 0.987 | 0.967 | 1.006 |
| Duration | 0.199 | 0.994 | 0.985 | 1.003 |
| Onset MGFA type | 0.394 | 1.235 | 0.760 | 2.006 |
| MGFA type at baseline | 0.097 | 1.432 | 0.937 | 2.188 |
| MSE within 6 months | < 0.001 | 4.134 | 1.734 | 9.854 |
| MSE within 1 year | 0.421 | 1.292 | 0.692 | 2.409 |
| With other auto-immune disease | 0.686 | 1.006 | 0.979 | 1.033 |
| Worsening of disease | 0.398 | 1.331 | 0.686 | 2.581 |
| Relapse of disease | 0.502 | 1.323 | 0.584 | 2.997 |
| With thymoma | 0.957 | 1.040 | 0.249 | 4.354 |
| Thymic surgery in this study | 0.329 | 0.597 | 0.213 | 1.679 |
| Thymic surgery prior to the baseline visit | 0.389 | 0.635 | 0.226 | 1.786 |
| AChR-ab positive | 0.221 | 3.462 | 0.474 | 25.265 |
| BMI | 0.044 | 0.477 | 0.233 | 0.981 |
| QMG ocular muscle score | 0.144 | 1.111 | 0.965 | 1.280 |
| QMG bulbar muscle score | 0.007 | 1.461 | 1.108 | 1.926 |
| QMG limb muscle score | 0.505 | 1.031 | 0.942 | 1.128 |
| QMG respiratory muscle score | 0.006 | 2.054 | 1.227 | 3.438 |
| QMG axial muscle score | 0.012 | 1.641 | 1.114 | 2.418 |
| QMG overall score | 0.016 | 1.089 | 1.016 | 1.167 |
| QOL-15 score | 0.686 | 1.292 | 0.979 | 1.033 |
| ADL bulbar muscle score | 0.057 | 1.202 | 0.994 | 1.453 |
| ADL respiratory muscle score | 0.767 | 0.894 | 0.425 | 1.880 |
| ADL limb muscle score | 0.538 | 1.078 | 0.849 | 1.369 |
| ADL ocular muscle score | 0.957 | 1.005 | 0.849 | 1.188 |
| ADL overall score | 0.124 | 1.105 | 0.973 | 1.256 |
MGFA, Myasthenia Gravis Foundation of America; MSE, minimal symptom expression; AChR-ab, acetylcholine receptor antibody; BMI: body mass index; QMG, quantitative myasthenia gravis; QOL, quality of life; ADL, Activities of Daily Living.